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ABSTRACT
The association between vitamin D levels and incident fractures in older men is uncertain. To test the hypothesis that low serum 25-
hydroxyvitamin D [(25(OH)D] levels are associated with an increased risk of fracture, we performed a case-cohort study of 436 men with
incident nonspine fractures, including 81 hip fractures, and a random subcohort of 1608 men; average follow-up time 5.3 years. Serum
vitamin D2 and vitamin D3 were measured on baseline sera using mass spectrometry and summed for total vitamin D. Modified Cox
proportional hazards models were used to estimate the hazard ratio (HR) of fracture with 95% confidence intervals (CIs). Multivariable
models included age, clinic, season, race, height, weight, and physical activity. The mean (SD) total 25(OH)D was 24.6 (7.8) ng/mL in
nonspine fracture subjects, 21.5 (7.9) ng/mL in hip fracture subjects, and 25.2 (7.8) ng/mL in controls (nonspine fracture subjects versus
nonpatients, p¼.14; hip fracture subjects versus controls, p<.0001). 25(OH)D levels were unrelated to nonspine fractures. One SD
decreaseintotal25(OH)Dwasassociatedwithanincreasedriskofhipfracture(multivariateHR¼1.60;95%CI1.18–2.17). Comparedwith
men in the top quartile of total 25(OH)D ( 28), the HR of hip fracture was 2.36 (95% CI 1.08–5.15) for men in the lowest quartile (<20)
(p¼.009 fortrend). Adjusting forhipbone mineral density attenuated the association by more than 50% (p¼.065 fortrend). Low serum
25(OH)D concentrations are associated with a higher risk of hip fracture in older men. Measurement of 25(OH)D may be useful in
identifying men at high risk of hip fracture.  2010 American Society for Bone and Mineral Research.
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Introduction
V
itamin D deficiency is common in older adults,
(1–3) including
community-dwelling seniors hospitalized for acute hip
fracture.
(4) An evidence-based report on vitamin D and bone
health concluded that the evidence for an association between
levels of serum 25-hydroxyvitamin D [25(OH)D] and fracture was
inconsistent
(5) and highlighted the paucity of data on circulating
vitamin D and fractures in men. Since publication of this review,
oneprospectivestudyreportednoassociationbetween25(OH)D
and fractures in men or women,
(6) while a second reported a
significantly lower risk of hip fracture in a pooled sample of men
and women with 25(OH)D levels greater than 24ng/mL.
(7) Low
circulating 25(OH)D levels have been linked to lower bone
mineral density (BMD), faster rates of bone loss, and higher bone
turnover,
(1) all of which could contribute to an association
between 25(OH)D and fracture. Vitamin D could contribute to
fractures by influencing muscle strength and balance, both of
which contribute to falls and disability.
(8–10) However, a meta-
analysis and at least one randomized, controlled trial did not
demonstrateareductioninfallsamongoldermentakingvitamin
D supplements.
(9,11) Finally, low levels of 25(OH)D have been
linked to frailty and poor health status, which also could
contribute to an association with fractures.
(10)
We conducted a case-cohort study within the Osteoporotic
Fractures in Men Study (MrOS) among 436 subjects with incident
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545fractures, including 81 hip fractures, and a randomly selected
subcohort of 1608 participants. We tested the following
hypotheses: (1) Low serum 25(OH)D concentrations are
associated with a higher risk of fracture, and (2) this association
may be mediated by poor health status, neuromuscular function,
body fat, BMD, or falls.
Materials and Methods
Study population
From March 2000 through April 2002, 5995 community-dwelling
men at six clinical centers in the United States (Birmingham,
Alabama, Minneapolis, Minnesota, Palo Alto, California, Mono-
ngahela Valley near Pittsburgh, Pennsylvania, Portland, Oregon,
and San Diego, California) agreed to participate in MrOS. Eligible
men were at least 65 years of age without bilateral hip
replacements and able to walk without the assistance of another
person. Details of the MrOS design and cohort have been
published.
(12,13) The institutional review board at each center
approved the study protocol, and written informed consent was
obtained from all participants.
Follow-up and outcome ascertainment
Men were sent questionnaires triannually to report any fractures.
All fractures were verified by medical records and confirmed by
blinded central adjudicators.
(14) Pathologic fractures were
excluded.
Case-cohort study design
This study is a case-cohort study nested within the
prospective design of MrOS. Men without sufficient serum
for vitamin D assays were excluded from all analyses. Of the
5908 eligible participants, we randomly selected 1608 men to
serve as the subcohort. In this subcohort, two participants
were excluded: one participant with insufficient serum and
another who had 25(OH)D levels more than 3 SD above the
mean (75.6ng/mL). The resulting 1606 men constituted the
subcohort for this study.
(15) We observed 435 incident
nonspine fractures (including 81 hip fractures) in the entire
cohort over the 5.3 years of follow-up. Among these subjects,
112 individuals also were sampled within the subcohort. The
totalstudysampleforthenonspinefractureanalysiswas1929
men (1494 subcohort and 435 fracture cases) and for hip
fracture analysis 1665 men (1584 subcohort and 81 hip
fracture cases).
Vitamin D assays
Fasting morning blood was collected, and sera were protected
from sunlight and stored at  708C until thawed for vitamin D
assays. Measures of vitamin D2 and vitamin D3 were performed
at the Mayo Clinic using mass spectrometry.
(16) Deuterated
stableisotope(d3-25-hydroxyvitamin D)was added toa 0.2mL
serum sample as internal standard. Vitamin D2,v i t a m i nD 3,a n d
the internal standard were extracted using acetonitrile
precipitation. The extracts then were further purified online
and analyzed by liquid chromatography–mass spectrometry/
mass spectrometry (LC-MS/MS) using multiple reaction
monitoring. Vitamin D2 and vitamin D3 were quantified,
reported individually, and summed for total 25(OH)D. The
minimum detectable limit for vitamin D2 was 4ng/mL;
vitamin D3, 2ng/mL. The interassay coefficient of variation
(CV) was 4.4%; intraassay CV, 4.9%. Vitamin D deficiency was
defined as total 25(OH)D<20ng/mL; insufficiency,a s2 1t o
29ng/mL; sufficiency,a s>30ng/mL.
(17)
Measurement of BMD and body composition
Bonemineraldensity(BMD,g/cm
2)ofthetotalhipwasmeasured
using dual-energy x-ray absorptiometry (DXA; QDR 4500W,
Hologic, Inc., Bedford, MA, USA). Standardized procedures for
participant positioning and scan analysis were used. All DXA
operators were centrally certified. Densitometry technicians at
the coordinating center reviewed a random sample of all the
scans, scans with exceptionally high or low BMD, and potentially
problematic scans flagged at the clinic to ensure adherence to
standardized techniques. Percent body fat was measured using
whole-body DXA scans.
Other measures
All covariates were assessed at baseline. Questionnaires
ascertained information on date of birth, race/ethnicity, history
of fracture, smoking, self-rated health, alcohol consumption,
history of falls 12 months before baseline, and weight at age 25.
Physical activity was assessed by asking men if they walked for
exercise. Grip strength was measured twice by a handheld
dynamometer (Jamar, Sammons Preston Rolyan, Bolingbrook, IL,
USA).
(18)
Time to complete chair stands and ability to stand from a
chair without using arms (yes/no) were also recorded. To test
dynamic balance, men were asked to stay within a narrow
w a l k i n gp a t h( 2 0 c m )o v e r6 m .M e nw i t ht w oo rf e w e r
deviations from the path were considered to have successfully
completed the trial, and a time for completion was recorded. A
participant was considered unable to complete this measure if
he had no successful trials after three attempts. Height (cm)
was measured on Harpenden stadiometers, and weight (kg)
was measured on a standard balance beam or digital scale
using standard protocols, with participants wearing light
clothing without shoes. Body mass index (BMI) was calculated
as kilograms per square meter (kg/m
2).
A modified Block Food Frequency Questionnaire was
administered to assess usual dietary and supplement intake
over the past year (Block Dietary Data Services, Berkeley, CA,
USA). Vitamin D and calcium intake were examined in these
analyses. Values for participants who reported a total of less
than 400 kcal/day were recorded as missing. At baseline,
participants were asked to bring in all medications used within
the last 30 days. All prescription medications recorded by the
clinics were stored in an electronic medications inventory
database. Each medication was matched to its ingredient(s)
based on the Iowa Drug Information Service (IDIS) Drug
546 Journal of Bone and Mineral Research CAULEY ET AL.Vocabulary (College of Pharmacy, University of Iowa, Iowa City,
IA, USA).
Statistical methods
Baseline characteristics were compared in the subcohort across
quartiles of total 25(OH)D using chi-square tests for categorical
variables and ANOVA for continuous variables. Wilcoxon non-
parametric tests were used for skewed covariates. Baseline
characteristics were also compared between fracture patients
and the random subcohort. Baseline characteristics that were
associated with fracture and 25(OH)D at p<.05 were identified as
confounders. Other covariates known to be confounders from the
literature also were selected. Associations between total serum
25(OH)D, vitamin D3,a n dv i t a m i nD 2 levels and incident fracture
wereassessed in proportionalhazards regression modelsmodified
for the case-cohort design. The base model included adjustment
for age, clinic, season, race, height, weight, and physical activity.
Hazard ratios (HRs) and 95% confidence intervals (CIs) were
calculated per standard deviation (SD), and per 10ng/mL
decrease in total 25(OH)D and vitamin D3 and across quartiles
defined on the basis of the distribution in the random cohort.
The highest quartile formed the referent group. Vitamin D2 was
undetectable in most men;
(19) we compared fracture risk in men
with detectable versus nondetectable vitamin D2. To assess for
nonlinear trends, restricted cubic spline Cox proportional hazard
models wereused to examinethe relationship between25(OH)D
levels and nonspine and hip fractures over the full range of
25(OH)D and vitamin D3.
(20) Knots were chosen at the 5th, 25th,
75th, and 95th percentiles, and the reference group in these
graphswasset to95thpercentile ofthe 25(OH)D level.Threshold
effects were performed by creating a spline variable at a
prespecified 25(OH)D level of 20ng/mL, and a test of equality
was done to determine if the slopes above and below the cut
point were equal. All spline graphs were adjusted for the
covariates in the base model.
To investigate mechanisms by which 25(OH)D might be
associated with fracture, we constructed the multivariate
base model and then added the following variables one at a
time to determine their impact on the associations between
Table 1. Baseline Characteristics of Men in the Subcohort Across Quartiles of Total 25(OH)D (ng/mL)
Characteristic
Random cohort (n¼1606)
p Value
Quartile 1
(3.13 to <19.0)
(n¼394)
Quartile 2
(19.0 to <27.9)
(n¼409)
Quartile 3
(25.1 to <27.9)
(n¼402)
Quartile 4
( 27.9)
(n¼401)
Age (yr) 74.6 6.3 73.9 6.1 74.0 5.7 72.7 5.47 .0002
Caucasian race 324 (82.2) 370 (90.5) 371 (92.3) 376 (93.8) <.0001
BMI (kg/m
2) 28.1 4.2 27.5 3.7 27.1 3.6 26.8 3.1 <.0001
Weight (kg) 84.8 14.5 83.6 13.5 82.4 12.8 82.0 11.2 .0104
Weight change since age 25 (kg) 12.0 12.4 10.7 11.2 10.5 10.9 9.2 10.1 .0289
% Total body fat 27.0 5.3 26.7 5.3 26.1 5.0 25.6 5.1 .0008
Height (cm) 173.5 6.9 174.3 6.7 174.2 7.0 175 6.7 .0243
Take vitamin D supplements 29 (7.7) 52 (13.5) 46 (11.8) 72 (18.8) .0001
Take calcium supplements 112 (29.6) 150 (38.9) 152 (39.1) 152 (39.5) .0111
Dietary vitamin D intake (IU/day) 144.5 105.9 162.8 110.8 173.0 122.5 166.1 119.5 .0032
Dietary calcium intake (mg/day) 740.5 362.0 796.1 397.6 826.3 391.2 812.00 392.7 .0179
Diet and supplements of
vitamin D (IU/day)
270.6 228.4 390.9 242.3 427.5 246.7 454.2 238.6 <.0001
Diet and supplements of
calcium (mg/day)
987.9 545.9 1151.2 599.0 1206.3 580.9 1243.9 625.0 <.0001
Currently smoking 21 (5.3) 17 (4.2) 12 (3.0) 9 (2.2) .1033
History of fracture after age 50 91 (23.1) 100 (24.5) 80 (20.0) 92 (23.0) .3818
Parental history of fracture 115 (39.5) 140 (44.4) 136 (44.7) 141 (45.2) .4676
History of falls in past 12 months 79 (20.1) 87 (21.3) 79 (19.7) 85 (21.2) .9206
Self-reported health status
a 318 (80.9) 343 (83.9) 345 (85.8) 363 (90.5) .0014
Total hip BMD (g/cm
2) 0.95 0.15 0.94 0.14 0.96 0.14 0.96 0.14 .0467
Oral corticosteroid use 12 (3.8) 9 (2.6) 12 (3.7) 10 (3.2) .8334
Unable to complete chair stands 14 (3.6) 14 (3.4) 6 (1.5) 6 (1.5) .0881
6 meter usual pace (m/s) 1.2 0.3 1.3 0.2 1.2 0.2 1.3 0.2 <.0001
Unable to attempt 20 cm narrow pace 65 (16.5) 42 (10.3) 42 (10.5) 20 (5.0) <.0001
Maximum grip strength (kg) 40.2 8.3 41.2 8.0 41.5 8.1 42.7 8.3 .0005
Takes walks for exercise 171 (43.4) 205 (50.1) 200 (56.6) 227 (56.6) .0031
Mean SD or n (%).
aPercent excellent/good.
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status, (3) neuromuscular function and balance (i.e., grip
strength, unable to complete narrow walk or complete chair
stand), (4) BMD, and (5) fall history (yes/no). We hypothe-
sized that the association between 25(OH)D and fracture
would be reduced after adjusting for these factors if they are
in the causal pathway. Because no clear cut point has been
published in the literature, a reduction of 10% of the HR was
used as support for the hypothesis of mediation. The
percentage reduction in HR was calculated as [(HRmodel1 –
HRmodel2)/(HRmodel1 –1 ) ]  100.
Results
Men with the highest total 25(OH)D were younger; more likely to
be Caucasian; had lower body weight, BMI, and percent body fat;
were taller; had better neuromuscular performance and BMD;
and also were more likely to take vitamin D and calcium
supplements and had higher intakes of dietary D and calcium
than men with the lowest 25(OH)D (Table 1). There were no
differences in smoking, personal or family history of fracture, or
falls.
Men who experienced any nonspine fracture were older, more
likely to be white, shorter in stature, more likely to report a
personal and parental fracture and falling in past 12 months, and
had lower BMD and worse neuromuscular function than men
who did not experience fracture (Table 2). Men who experienced
a hip fracture also were older, had a lower BMI and body weight,
had gained less weight since age 25, and had a lower vitamin D
intake and BMD and worse neuromuscular function than men
without a hip fracture. There were no differences in smoking,
self-reported health status, use of corticosteroids, or use of
Table 2. Baseline Characteristics Comparing Men Who Experienced a Fracture With Men Who Were Fracture Free
Baseline characteristics
No nonspine
fracture (n¼1494)
Nonspine
fracture (n¼435)
No hip
fracture (n¼1584)
Hip
fracture (n¼81)
Age, mean (year) 73.7 5.9 75.5 6.5
     73.7 5.9 79.8 5.9
    
Caucasian race 1337 (89.5) 410 (94.3)
   1419 (89.6) 77 (95.1)
BMI (kg/m
2) 27.4 3.7 27.2 4.0 27.4 3.7 26.5 3.8
 
Weight (kg) 83.4 13.1 82.2 13.9 83.3 13.1 78.9 12.6
  
Weight change since age 25 (kg) 10.7 11.2 10.2 12.6 10.7 11.1 7.0 12.9
 
Percent total body fat 26.3 5.2 26.7 5.9 26.4 5.2 26.3 5.8
Height (cm) 174.4 6.8 173.6 7.2 174.3 6.9 172.4 6.3
 
Season of blood draw
Winter 304 (20.4) 79 (18.2) 317 (20.0) 14 (17.3)
Spring 386 (25.8) 119 (27.4) 411 (26.0) 24 (29.6)
Summer 430 (28.8) 136 (31.3) 455 (28.7) 26 (32.1)
Fall 374 (25.0) 101 (23.2) 401 (25.3) 17 (21.0)
Take vitamin D supplements 186 (13.0) 64 (15.7) 195 (12.9) 11 (14.7)
Take calcium supplements 527 (36.8) 167 (40.4) 559 (36.8) 29 (38.7)
Dietary vitamin D intake (IU/day) 162.9 116.2 160.1 106.7 162.0 115.2 144.3 108.2
Dietary calcium intake (mg/day) 796.8 390.3 773.4 374.2 794.1 387.3 744.1 426.6
Diet and supplements of
vitamin D (IU/day)
390.3 249.3 376.0 240.3 387.5 248.6 323.4 237.9
 
Diet and supplements of
calcium (mg/day)
1151.1 600.0 1152.4 595.6 1148.1 595.9 1118.3 681.8
Currently smoking 55 (3.7) 15 (3.5) 58 (3.7) 4 (4.9)
History of fracture after age 50 319 (21.4) 175 (40.2)
     352 (22.3) 39 (48.2)
    
Parental history of fracture 488 (42.9) 167 (50.6)
  522 (43.3) 30 (50.0)
History of falls within the past 12 months 289 (19.3) 142 (32.6)
     323 (20.4) 25 (30.9)
 
Good to excellent health status 1272 (85.2) 365 (83.9) 1352 (85.4) 65 (80.3)
Total hip BMD (g/cm
2) 0.96 0.14 0.89 0.15
     0.96 0.14 0.79 0.14
    
Oral corticosteroid use 41 (3.4) 10 (2.8) 42 (3.3) 2 (3.0)
Unable to complete chair stands 38 (2.6) 25 (5.8)
    38 (2.4) 11 (13.8)
    
Unable to attempt 20 cm narrow pace 146 (9.8) 70 (16.1)
    161 (10.2) 20 (24.7)
    
Maximum grip strength (kg) 41.6 8.2 39.7 9.0
    41.5 8.2 36.6 7.8
    
Takes walks for exercise 747 (50.0) 197 (45.3) 793 (50.1) 34 (42.0)
Mean SD or n (%).
 p<.05 vs. controls.
  p<.01 vs. controls.
   p<.001 vs. controls.
    p<.0001 vs. controls.
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fracture patients and nonpatients.
Serum vitamin D and fracture
The mean total 25(OH)D level was 16% lower in hip fracture
patients than in the subcohort, but there was no difference in
total 25(OH)D levels between men with any nonspine fracture
versus controls (Table 3). Almost half the men who suffered a hip
fracture had total 25(OH)D levels in the deficient range
(<20.0ng/mL; 7% had values less than 10ng/mL). Vitamin D3
levels were 15% lower among men who suffered a hip fracture
compared with controls. A slightly lower proportion of hip
fracture patients did not have measurable vitamin D2 levels, but
this was not statistically significant.
Total 25(OH)D, vitamin D3, and vitamin D2 were unrelated to
the risk of nonspine fracture (Table 4). The adjusted HR for
incident nonspine fracture per 1 SD decrease in total 25(OH)D
was1.07(95%CI0.96–1.21).Tofurtherexploretherelationshipof
vitamin D to nonspine fracture, we stratified by age. There was
no evidence of an association between vitamin D and nonspine
fracture even in the oldest (age   80 years; data not shown).
Table 3. Serum 25(OH)D Levels (ng/mL) by Fracture Status
No nonspine fracture Nonspine fracture No hip fracture Hip fracture
Total 25(OH)D
Mean SD 25.16 (7.85) 24.55 (7.76) 25.15 (7.89) 21.15 (7.92)
  
Median (range) 25.10 (3.13–58.30) 24.80 (4.36–55.2) 25.1 (3.10–58.3) 20.6 (4.4–40.6)
<20ng/mL, n (%) 372 (24.90) 116 (26.67) 395 (24.94) 37 (45.68)
  
20 to <30ng/mL, n (%) 755 (50.54) 225 (51.72) 797 (50.32) 33 (40.74)
 30ng/mL, n (%) 367 (24.56) 94 (21.61) 392 (24.75) 11 (13.58)
Vitamin D3
Mean SD 22.91 (8.31) 22.37 (8.27) 22.95 (8.34) 19.61 (8.08)
 
Median (range) 22.40 (2.40–58.30) 22.40 (4.20–55.20) 22.6 (2.4–58.3) 19.2 (4.4–40.6)
Vitamin D2
>0ng/mL, n (%) 396 (26.51) 113 (25.98) 417 (26.33) 14 (17.28)
 p<.001 versus controls.
  p¼.0001 versus controls.
Table 4. Relative Hazard (RH) (95% CI) of Nonspine Fracture or Hip Fracture by Serum 25(OH)D Levels (ng/mL)
Nonspine fracture RH (95% CI)
a Hip fracture RH (95% CI)
a
Total 25(OH)D
Per SD (7.9) 1.07 (0.96–1.21) 1.60 (1.18–2.17)
Per 10ng/mL 1.11 (0.94–1.27) 1.85 (1.27–2.69)
Quartiles
1st (3.13 to <19.0) 1.21 (0.86–1.65) 2.36 (1.08–5.16)
2nd (19.0 to <25.1) 1.15 (0.84–1.56) 1.48 (0.68–3.21)
3rd (25.1 to <27.9) 1.13 (0.81–1.53) 0.98 (0.42–2.28)
4th ( 27.9) Referent Referent
p trend .2927 .0093
Vitamin D3
Per SD (8.3) 1.06 (0.95–1.19) 1.42 (1.05–1.91)
Per 10ng/mL 1.08 (0.94–1.23) 1.52 (1.06–2.16)
Quartiles
1st (2.07 to <17.0) 1.17 (0.86–1.61) 1.54 (0.77–3.09)
2nd (17.0 to <22.4) 1.02 (0.74–1.40) 1.41 (0.71–2.80)
3rd (22.4 to <28.2) 1.19 (0.88–1.62) 0.57 (0.25–1.34)
4th ( 28.2) Referent Referent
p trend .55 .049
Vitamin D2 1.00 1.00
>0 vs. 0 1.01 (0.78–1.28) 0.62 (0.33–1.17)
p value 0.97 0.14
aBase model adjusting for age, race, clinic, season of blood draw, physical activity, height, and weight.
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higher risk of hip fracture; the adjusted HR of hip fracture per 1
SD decrease in total 25(OH)D was 1.60 (95 % CI 1.18–2.17). Men
with the lowest total 25(OH)D levels had a greater than twofold
increased risk of hip fracture compared with men with the
highest total 25(OH)D levels (HR¼2.36; 95% CI 1.08–5.16;
p¼.009 for trend).
The association between vitamin D3 and fractures was similar
but weaker. A 1 SD decrease in vitamin D3 was associated with a
42% increased risk of hip fracture. Men in the lowest quartile of
vitamin D3 had a 54% increased risk of hip fracture compared
with men with the highest vitamin D3 level (p¼.049 for linear
trend). Men with measurable vitamin D2 had a lower risk of hip
fracture, but confidence intervals were wide, and this association
was not significant.
Examination of the association over the full range of total
25(OH)D levels revealed no association with nonspine fracture
(Fig. 1). For hip fractures, there was no evidence of a threshold
(for test for nonequal slopes, p¼.59), although the slope for hip
fractures was steepest in men with a total 25(OH)D less than
20ng/mL (Fig. 2).
Potential mediators
Inclusion of percent body fat, health status, or neuromuscular
function in the models reduced the HR by 22%, 10%, and 18%,
respectively, suggesting some mediating role of these para-
meters in the relationship between total 25(OH)D and hip
fracture (Table 5). However, total hip BMD reduced the HR by
more than 50%, suggesting a major role for BMD in mediating
this association. Inclusion of baseline information on falls had no
effect on the HR.
For vitamin D3, inclusion of percent body fat and neuromus-
cular measures reduced the HR by 35% and 17%, respectively.
InclusionofhealthstatusorfallsinthemodelsreducedtheHRby
less than 10%. Adjustment for total hip BMD completely
attenuated the association between and vitamin D3 and hip
fracture.
Discussion
In our prospective case-cohort study, we found that men with
the lowest total 25(OH)D concentration (<19.9ng/mL) at study
entry had a significantly increased risk for subsequent hip
fractures during the next 5 years over men with the highest
concentrations ( 27.9ng/mL). A similar association was
observed between vitamin D3 and hip fracture, but vitamin D2
was unrelated to hip fractures. Vitamin D concentrations were
not related to risk of any nonspine fractures, suggesting an
association with more frailty-related fractures.
Toourknowledge,fewstudieshaveexaminedtherelationship
between total 25(OH)D and fractures in older men. Five of 12
case-control studies included men, and all reported lower
25(OH)D levels in men with acute hip fracture compared with
controls.
(5)Onlythreeprospectivestudiesincludedmen.Woo
(21)
studied 427 patients, including 171 men. Subjects who
experienced an incident fracture had lower total 25(OH)D levels,
but the relationship was not significant. The association between
total 25(OH)D and fracture was studied in 730 incident fracture
patients (155 men) and 1445 matched controls (309 men).
(6)
There was no evidence of an association between 25(OH)D and
fracture in men or women. These results are consistent with our
findings that 25(OH)D concentrations were unrelated to all
nonspine fractures. There were too few hip fractures (n¼5) to
examine hip fractures separately.
Fig. 1. Restricted cubic spline plots of hazard ratios of nonspine with
25(OH)D.
Fig. 2. Restricted cubic spline plots of hazard ratios of hip fracture with
25(OH)D.
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Third National Health and Nutrition Examination Survey
(NHANES III), in which the relative risk for hip fracture was
significantly reduced in subjects with 25(OH)D concentrations
greater than 25ng/mL.
(7) This study included 62 men with hip
fractures and 869 control men, but results were not stratified by
gender. Our results also are consistent with a recent report in
women that low total serum 25(OH)D levels are associated with
an increased risk of hip fracture.
(22)
We studied several possible mechanisms whereby 25(OH)D
concentrations may influence hip fracture risk. The increased
fracture risk could be related to impaired muscle strength and
balance and poor health status, all of which could increase the
risk of falls and subsequently fracture.
(8–10) Inclusion of health
status or neuromuscular function reduced the HR by 10% and
18%, respectively, meeting our criteria for mediation. Lower
bioavailability of vitamin D in obese patients and inverse
associations between 25(OH)D and adiposity have been
reported.
(23–25) Low fat mass and body weight have been linked
toanincreasedriskofhipfracture.
(26)Hencethehigherdegreeof
adiposity in men with the lowest 25(OH)D levels could confound
our results. Adjusting for percent body fat in our analyses
resulted in a 22% attenuation in the HR association. Surprisingly,
addition of falls had little effect on the relationship between
25(OH)D and hip fracture, perhaps because we assessed falls at
baseline and did not adjust for falls over the follow-up period.
Low circulating vitamin D has been shown to affect bone
strength.
(1) Vitamin D deficiency in milder forms can lead to
secondary hyperparathyroidism and subsequently faster rates of
bone turnover and bone loss. Positive relationships have been
observed between serum 25(OH)D and BMD.
(27,28) Adjustment
for BMD attenuated the association between total 25(OH)D and
hipfracturesuchthattheoveralltrendwasborderlinesignificant.
Adjustment for BMD completely attenuated the relationship
bewteen vitamin D3 level and hip fracture. This suggests that the
association between low vitamin D level and increased hip
fracture risk is at least in part due to lower hip BMD among the
men with low vitamin D levels. This result differs from the
NHANES III study, where the relationship between 25(OH)D and
hip fracture was independent of BMD.
(7) Low BMD is associated
with an increased risk of all nonspine fractures,
(29) and if BMD is
the mediator, it is somewhat surprising that there was no
relationship between 25(OH)D and nonspine fracture. The
relationship between BMD and nonspine fracture is, however,
weaker than for hip fracture. Further studies are needed to
confirm the mechanism underlying the association of 25(OH)D
and hip fracture. In particular, future studies should include
markers of bone turnover. In women, we observed that high
bone resorption may be an important mechanism for the
association between low 25(OH)D and hip fracture.
(22)
The optimal serum 25(OH)D concentration needed to maintain
bone health has not been established. Optimal concentrations
have been defined as those at which serum parathyroid hormone
levels plateau in the normal range;
(30) however, this definition has
led to a wide range of optimal 25(OH)D concentration thresholds
(8–46ng/mL). More recently, the optimal threshold concentration
of 25(OH)D, based on BMD levels, was found to be at least 31ng/
mL, with a target of 37–42ng/mL.
(28) Randomized trials of vitamin
D supplementation that brought mean serum 25(OH)D concen-
trations up to 30–41ng/mL found significantly lower fracture
rates.
(31) Trials in which the mean serum 25(OH)D concentration
did not reach this threshold showed no effect on fractures.
(32,33)
Our results showed the greatest risk of hip fracture among men
with a 25(OH)D level of less than 19.9ng/mL, consistent with our
recentfindingsamongolderwomen.
(22)This suggests a somewhat
lower threshold for defining ‘‘optimal’’ levels by hip fracture risk,
although the threshold model was not significant, and we had
limited power to detect a threshold.
Table 5. Relative Hazard (95% CI) of Hip Fracture According to Total 25(OH)D and Vitamin D3 Levels: Effect of Adjustment for Possible
Mediators
Quartile of Total 25(OH)D (ng/mL)
p for
linear trend
1st
(3.13 to <19.0)
2nd
(19.0 to <25.1)
3rd
(25.1 to <29.9)
4th
( 29.9)
Total 25(OH)D
Base
a 2.36 (1.08–5.15) 1.48 (0.68–3.21) 0.98 (0.42–2.28) Ref .009
Base
aþpercent of body fat 2.06 (0.93–4.57) 1.40 (0.64–3.08) 0.91 (0.39–2.14) Ref .029
Base
aþhealth status 2.22 (1.02–4.83) 1.40 (0.64–3.06) 0.95 (0.41–2.22) Ref .014
Base
aþneuromuscular measures
b 2.11 (0.94–4.75) 1.45 (0.66–3.22) 0.86 (0.35–2.12) Ref .019
Base
aþhip BMD 1.64 (0.73–3.68) 0.99 (0.44–2.23) 0.68 (0.27–1.68) Ref .065
Base
aþfalls 2.38 (1.09–5.20) 1.51 (0.69–3.26) 0.99 (0.42–2.30) Ref .009
Vitamin D3
Base 1.54 (0.77–3.09) 1.41 (0.71–2.91) 0.57 (0.25–1.34) Ref .049
Base
aþpercent of body fat 1.35 (0.66–2.77) 1.44 (0.71–2.92) 0.61 (0.26–1.44) Ref .128
Base
aþhealth status 1.50 (0.75–3.00) 1.32 (0.66–2.64) 0.56 (0.24–1.32) Ref .057
Base
aþneuromuscular measures
b 1.44 (0.68–3.05) 1.37 (0.67–2.81) 0.59 (0.24–1.45) Ref .103
Base
aþHip BMD 1.03 (0.48–2.22) 0.98 (0.49–1.97) 0.46 (0.20–1.08) Ref .387
Base
aþfalls 1.56 (0.78–3.14) 1.44 (0.72–2.86) 0.57 (0.24–1.34) Ref .045
aBase model adjusting for age, race, clinic, season of blood draw, physical activity, weight, and height.
bNeuromuscular measures: unable to complete chair stands or narrow walk; grip strength.
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vitamin D2, and vitamin D3. Results generally were similar
between total 25(OH)D and vitamin D3, albeit a bit weaker for
vitamin D3. We found no relationship with vitamin D2, but the
majority of men did not have measurable vitamin D2. The major
determinant of having measurable vitamin D2 was self-report of
vitamin D supplements.
(19) At the time that the serum was
collected, vitamin D supplementation was limited primarily to
vitamin D2. This implies that the level of supplement used by
these men was ineffective in preventing hip fractures. Never-
theless, the clinical advantage of measuring both vitamin D2 and
vitamin D3 separately is uncertain and has been shown to cause
some clinical confusion.
(34) Results were strongest for total
25(OH)D, and it is currently recommended that separate
reporting should not be carried out until the clinical utility
has been demonstrated.
Our study has several limitations. Nonwhite men are more
likely to be vitamin D deficient;
(17) however, most of the fractures
occurred in white men. We do not have measures of parathyroid
hormone, which could contribute to the relationship between
25(OH)D and hip fracture.
(1) Finally, few men had 25(OH)D
concentrations greater than 30ng/mL, so we could not test
whether even higher concentrations offer greater protection
against hip fracture.
Despite these limitations, we conclude that low serum
25(OH)D concentrations are associated with an increased risk
of hip fracture in community-dwelling men. Low BMD may
contribute to this association. Similar to our results in older
women,
(22) our findings suggest that low serum 25(OH)D
concentrations may help to identify men at high risk of hip
fracture.
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